Dare Bioscience (DARE) Capital Expenditures Growth (1y) (2014 - 2025)
Dare Bioscience (DARE) Capital Expenditures Growth (1y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.90% |
| Sep 30, 2025 | 50.61% |
| Jun 30, 2025 | -99.22% |
| Mar 31, 2025 | -299.22% |
| Dec 31, 2024 | 2,474.59% |
| Sep 30, 2024 | 355.53% |
| Jun 30, 2024 | -117.80% |
| Dec 31, 2023 | 65.48% |
| Sep 30, 2023 | -112.43% |
| Jun 30, 2023 | 1,179.10% |
| Dec 31, 2022 | -80.87% |
| Sep 30, 2022 | 946.97% |
| Dec 31, 2021 | -1,587.89% |
| Dec 31, 2016 | -73.53% |
| Sep 30, 2016 | -20.59% |
| Jun 30, 2016 | 44.87% |
| Mar 31, 2016 | 1,137.93% |
| Dec 31, 2015 | 24.77% |
| Sep 30, 2015 | -56.41% |
| Jun 30, 2015 | 107.95% |